COG

Liberty Gold Reports Year-End 2023 Financial and Operating Results

Retrieved on: 
Thursday, March 28, 2024
Mining, Biophysical environment, Inference, LGD, Gold, Sale, NSR, Table, COG, TSX, Social, OTCQX, Rare-earth element

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the “Company”), is pleased to announce its financial and operating results for the fiscal year ended December 31, 2023.

Key Points: 
  • VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the “Company”), is pleased to announce its financial and operating results for the fiscal year ended December 31, 2023.
  • On September 5, 2023, published second annual Environmental, Social and Governance report: Developing Gold Deposits in a Responsible and Sustainable Manner2.
  • On November 8, 2023, announced the appointment of Cal Everett as Chief Executive Officer and Jon Gilligan as President, effective November 10, 20233.
  • Completed 2023 RC exploration drilling program as of December 31, 2023, for a total of 27,461 meters drilled.

Hyundai Hope On Wheels Reaches a Lifetime Giving Milestone of a Quarter-Billion Dollars in 2024

Retrieved on: 
Wednesday, March 27, 2024
Research, Health, Cole, Survival rate, Disease, Hyundai Motor America, Patient, Hospital, Children's Oncology Group, Cancer, Hope, Life, Organic, COG, Hyundai, Multimedia, Courage, National Youth, Estate (law)

With this commitment, the organization reaches a lifetime giving milestone of a quarter-billion dollars as part of its 26th anniversary.

Key Points: 
  • With this commitment, the organization reaches a lifetime giving milestone of a quarter-billion dollars as part of its 26th anniversary.
  • "We are proud to have reached this incredible milestone for Hyundai Hope On Wheels, as it truly speaks to the commitment of Hyundai Motor America and its dealers to the cause of ending childhood cancer," said Kevin Reilly, vice chairman of the Hyundai Hope On Wheels Board of Directors, and president of Alexandria Hyundai.
  • Later this year, Hyundai Hope On Wheels will visit children's hospitals across the nation to present Hope On Wheels grant awards.
  • Primary funding for Hyundai Hope On Wheels comes from Hyundai Motor America and its more than 830 U.S. dealers.

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024
Incidence, Osteosarcoma, Fennec, FDA, TSX, Food, Neuroblastoma, Germ cell tumor, Hepatoblastoma, Risk, Literacy, Safety, Audit, Cisplatin, Hearing loss, Medulloblastoma, Kool-Aid, Ototoxicity, Food and Drug Administration, Patient, Survival, FENC, COG

RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.

Key Points: 
  • ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~
    RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.
  • The information in this press release is based upon preliminary unaudited information and management estimates for the fourth quarter 2023 and is subject to the completion of Fennec’s financial closing procedures and year end audit.
  • Preliminary Unaudited 2023 Fourth Quarter Revenue and Year End Performance:
    Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.
  • Fennec expects to report its 2023 fourth quarter and audited full-year year results of operations on or about March 26, 2024.

City of Hope Children’s Cancer Center, Children’s Oncology Group conduct largest clinical trial seeking to prevent heart failure among childhood cancer survivors

Retrieved on: 
Tuesday, January 9, 2024
Research, General Health, Pharmaceutical, Oncology, Consumer, Hospitals, Genetics, Clinical Trials, Science, Children, Cardiology, Biotechnology, Health, Adolescence, Patient, Leukemia, Heart, Hospital, City, Multimedia, Facial muscles, Survivor, Heart failure, The Lancet, Society, Cancer, NCI, Risk, Leukemia & Lymphoma Society, Charitable organization, National Cancer Institute, Physician, Clinical trial, COG, Haematopoietic system, Bangladesh Technical Education Board, Carvedilol, Blood, Medical imaging

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children’s Oncology Group (COG) , have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

Key Points: 
  • Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children’s Oncology Group (COG) , have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.
  • View the full release here: https://www.businesswire.com/news/home/20240109428042/en/
    Physicians at City of Hope Children's Cancer Center, in cooperation with the Children’s Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.
  • Unfortunately, after the onset of heart function decline, the downward cascade is irreversible, highlighting an urgent need for early prevention strategies.
  • “The growing number of childhood cancer survivors makes the development of early interventions imperative.

BOE Varitronix opens new horizon of smart mobility at CES 2024

Retrieved on: 
Thursday, January 11, 2024
Aion, OLED, SVC, Glass, Temperature, Multimedia, Marriage, Deep learning, Relaxation, AI, Geely Auto, Thyroid function tests, Software, Hyper, Gold, Travel, Electronics, HERO, Transport, CES, GAC, Cell, COG, LED-backlit LCD, TFT, Consumer electronics, NTSC, Television

LAS VEGAS, Jan. 11, 2024 /PRNewswire/ -- BOE Varitronix Limited, the global automotive display arm of BOE, presented a host of futuristic automotive display products and smart cockpit solutions at the Consumer Electronics Show 2024 (CES 2024) from January 9 to 12, local time.

Key Points: 
  • LAS VEGAS, Jan. 11, 2024 /PRNewswire/ -- BOE Varitronix Limited, the global automotive display arm of BOE, presented a host of futuristic automotive display products and smart cockpit solutions at the Consumer Electronics Show 2024 (CES 2024) from January 9 to 12, local time.
  • During the show, BOE Varitronix Limited held a product launch themed "Smart Display, Green Mobility," unveiling new technologies, products, and forms that revolutionize smart cockpit and set the trends in smart mobility.
  • This also signifies that BOE Varitronix Limited has pioneered the mass production of large-size oxide TFT automotive displays.
  • At CES 2024, the showcase of BOE Varitronix Limited culminated in the product launch themed "Smart Display, Green Mobility."

Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

Retrieved on: 
Monday, December 18, 2023
Lung cancer, National Cancer Institute, Partnership, Neuroblastoma, Research, FDA, Colorectal cancer, Polyamine, PBLA, Multiple myeloma, NDA, Prostate cancer, MSN, Doctor of Philosophy, Therapy, COG, USWM, Eflornithine, Cancer, New Drug Application, Patient, NCI, Pharmaceutical industry

The approval of USWM’s NDA for the use of eflornithine for the treatment of patients with high-risk neuroblastoma marks the first FDA approval of an NDA for any polyamine targeted therapy in a cancer indication.

Key Points: 
  • The approval of USWM’s NDA for the use of eflornithine for the treatment of patients with high-risk neuroblastoma marks the first FDA approval of an NDA for any polyamine targeted therapy in a cancer indication.
  • In July 2023, Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5 million of non-dilutive funding, including payments upon USWM’s successful completion of milestones related to eflornithine's clinical development, regulatory approval, and commercial sales.
  • “The FDA’s approval of USWM’s eflornithine NDA for high-risk neuroblastoma is an exciting milestone in our partnership.
  • This demonstrates the potential for polyamine targeted therapies in cancer,” said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.

Giving Tuesday 2023: DCG Giving, a Dave Cantin Group Nonprofit, Donates More Than a Quarter Million Dollars to Boost Pediatric Cancer Research and Treatment Nationwide

Retrieved on: 
Tuesday, November 28, 2023
NADA, National Cancer Institute, Hospital, Hope, University, DCG, Crystal, Acute lymphoblastic leukemia, Survival rate, Research, Children's Hospital Los Angeles, Lymphoid leukemia, Organic, COG, Rutgers University, Cancer, Pharmaceutical industry

“I am grateful to all the benefactors within the automotive industry who supported DCG Giving with their generous donations.

Key Points: 
  • “I am grateful to all the benefactors within the automotive industry who supported DCG Giving with their generous donations.
  • This critical funding for clinical research will help transform the lives of children and young adults,” said Dave Cantin, President and CEO of The Dave Cantin Group.
  • This event focused the automotive industry’s attention on the great need for more childhood cancer research funding.
  • DCG Giving continually supports local pediatric cancer charities from coast to coast.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023
Cisplatin, Literacy, Food and Drug Administration, Neuroblastoma, FENC, Safety, COG, Food, GMT, Ototoxicity, Incidence, Risk, Patient, Medulloblastoma, FDA, Hepatoblastoma, Conference, Kool-Aid, Germ cell tumor, Survival, Hearing loss, RESEARCH, Osteosarcoma, TSX, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • Event: Jefferies London Healthcare Conference in London, UK
    Time: Company Presentation at 5:00 a.m.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.

Himax Commences World’s First Mass Production of LTDI Automotive Display Solution for NEVs

Retrieved on: 
Wednesday, October 11, 2023
AEC, NEV, NEVS, COG, Safety, COF, System, Comply or explain, CES, Longevity, Mobile phone, Television, Himax, Somatosensory system

LTDI design is particularly suitable for prevailing NEVs, known for their stylish smart cabins that feature large-sized display, panoramic view, free-form, curved design and in-cell touch functions.

Key Points: 
  • LTDI design is particularly suitable for prevailing NEVs, known for their stylish smart cabins that feature large-sized display, panoramic view, free-form, curved design and in-cell touch functions.
  • The Company has received a proliferation of inquiries regarding its LTDI solution which is now universally adopted by panel makers across the board.
  • With the introduction of innovative display technology, car manufacturers have redefined the functionality of dashboards and central consoles, transforming them into an integrated, panoramic cockpit display with touch features.
  • Complies with leading automotive standards: Conforms to automotive AEC-Q100 reliability specifications and the latest automotive ISO 26262 functional safety requirements.

OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence

Retrieved on: 
Tuesday, September 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Fast, Clinical trial, OS, Cancer, AYA, RDD, COG, BTD, Prognosis, Rated R, HIV disease progression rates, USDA, Patient, Physician, Principle, OST, Recurrence, Metastasis, Disease, Pharmaceutical industry, Osteosarcoma, MD

OS Therapies, a research and clinical stage biopharmaceutical company, is extremely excited to announce Full Enrollment for its lead OST-HER2 (OST31-164) program in its ongoing clinical trial AOST-2121 (NCT04974008).

Key Points: 
  • OS Therapies, a research and clinical stage biopharmaceutical company, is extremely excited to announce Full Enrollment for its lead OST-HER2 (OST31-164) program in its ongoing clinical trial AOST-2121 (NCT04974008).
  • “Several patients have completed the treatment phase of the trial and many more are undergoing treatment with OST-HER2.
  • OS Therapies has two platform technologies: OST-HER2 and OST-TDC being developed for therapies to treat Osteosarcoma (OS) and other solid tumors including ovarian.
  • AOST-2121 is a Phase IIB clinical trial intended to prevent or delay metastasis and improve Overall Survival (OS) in Osteosarcoma.